Pluri Inc. Files 2024 Annual Report

TL;DR

Pluri Inc. dropped its 2024 10-K. Check financials & risks.

AI Summary

Pluri Inc. filed its annual report (10-K) for the fiscal year ended June 30, 2024. The company, formerly known as Pluristem Therapeutics Inc., is involved in biological products. The filing details its business operations, financial condition, and risk factors. Pluri Inc. is incorporated in Nevada and headquartered in Haifa, Israel.

Why It Matters

This 10-K filing provides investors and stakeholders with a comprehensive overview of Pluri Inc.'s performance and strategic direction for the past fiscal year, including any significant developments or challenges.

Risk Assessment

Risk Level: medium — As a company in the biological products sector, Pluri Inc. likely faces inherent risks related to research and development, regulatory approvals, and market adoption.

Key Numbers

• 001-31392 — SEC File Number (Identifies the company's filings with the SEC.)
• 0001158780 — Central Index Key (Unique identifier for the company in SEC filings.)

Key Players & Entities

• Pluri Inc. (company) — Filer of the 10-K
• June 30, 2024 (date) — Fiscal year end
• Pluristem Therapeutics Inc. (company) — Former name of Pluri Inc.
• Nevada (location) — State of incorporation
• Haifa, Israel (location) — Business address

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Shares, par value $0.00001 PLUR The Nasdaq Capital Market Securi
• $4.2 million — e announced that we signed a three-year $4.2 million contract with the U.S. National Institu
• $10 million — fering, for aggregate gross proceeds of $10 million. As part of the Offering, we invested $
• $1.25 million — n. As part of the Offering, we invested $1.25 million. In addition, the Subsidiary and Ever A

Filing Documents

• ea0213910-10k_pluriinc.htm (10-K) — 1343KB
• ea021391001ex4-1_pluriinc.htm (EX-4.1) — 12KB
• ea021391001ex10-34_pluriinc.htm (EX-10.35) — 126KB
• ea021391001ex21-1_pluriinc.htm (EX-21.1) — 1KB
• ea021391001ex23-1_pluriinc.htm (EX-23.1) — 2KB
• ea021391001ex31-1_pluriinc.htm (EX-31.1) — 10KB
• ea021391001ex31-2_pluriinc.htm (EX-31.2) — 10KB
• ea021391001ex32-1_pluriinc.htm (EX-32.1) — 3KB
• ea021391001ex32-2_pluriinc.htm (EX-32.2) — 3KB
• ea021391001ex97-1_pluriinc.htm (EX-97.1) — 39KB
• image_001.jpg (GRAPHIC) — 2KB
• 0001213900-24-079861.txt ( ) — 6708KB
• plur-20240630.xsd (EX-101.SCH) — 68KB
• plur-20240630_cal.xml (EX-101.CAL) — 42KB
• plur-20240630_def.xml (EX-101.DEF) — 275KB
• plur-20240630_lab.xml (EX-101.LAB) — 559KB
• plur-20240630_pre.xml (EX-101.PRE) — 287KB
• ea0213910-10k_pluriinc_htm.xml (XML) — 718KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 16 Item 1B. Unresolved Staff Comments 33 Item 1C. Cybersecurity 34 Item 2.

Properties

Properties 35 Item 3.

Legal Proceedings

Legal Proceedings 35 Item 4. Mine Safety Disclosures 35 PART II 36 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 36 Item 6. [Reserved] 36 Item 7.

Management's Discussion and Analysis of Financial

Management's Discussion and Analysis of Financial Condition and Results of Operations 36 Item 7A.

Quantitative and Qualitative Disclosures About Market

Quantitative and Qualitative Disclosures About Market Risk 43 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data F-1 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 44 Item 9A.

Controls and Procedures

Controls and Procedures 44 Item 9B. Other Information 44 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 44 PART III 45 Item 10. Directors, Executive Officers and Corporate Governance 45 Item 11.

Executive Compensation

Executive Compensation 50 Item 12. Security 55 Item 13. Certain Relationships and Related Transactions and Director Independence 57 Item 14. Principal Accounting Fees and Services 57 PART IV 58 Item 15. Exhibits and Financial Statement Schedules 58 Item 16. Form 10-K Summary 60 i Our financial statements are stated in thousands United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles, or U.S. GAAP. In this annual report, unless otherwise specified, all dollar, amounts are expressed in U.S. dollars. As used in this annual report, the terms "we", "us", "our", the "Company", and "Pluri" mean Pluri Inc., our wholly owned Israeli subsidiary, our majority owned Israeli subsidiary, and the wholly owned subsidiary of our Israeli subsidiary in Germany, unless otherwise indicated or required by the context. All information in this Annual Report on Form 10-K or Annual Report, relating to shares or price per share reflects the 1-for-8 reverse stock split effected by us on April 1, 2024. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS The within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as "believes," "intends," "plans," "expects," "may," "will," "should," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, and similar expressions are intended to identify forward-looking and other factors and involve know

View Full Filing

View this 10-K filing on SEC EDGAR